Author: admin

“Lung Fibrosis Pipeline Insight, 2025” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lung Fibrosis Market.

The Lung Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Lung Fibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Lung Fibrosis treatment therapies with a considerable amount of success over the years.

• Lung Fibrosis companies working in the treatment market are Genentech, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Assistance Publique – Hôpitaux de Paris, Pfizer, Zambon SpA, Centocor, Inc., Tvardi Therapeutics, Bristol-Myers Squibb, PureTech, Endeavor Biomedicines, Syndax Pharmaceuticals, SPARK Biopharma, CSL Behring, and others, are developing therapies for the Lung Fibrosis treatment

• Emerging Lung Fibrosis therapies in the different phases of clinical trials are- Pirfenidone, BMS-986278, BI 1839100, Pirfenidone, Etanercept, n-acetylcysteine, CNTO 888, TTI-101, BMS-986278, Pirfenidone, taladegib, Axatilimab, SB17170, Garadacimab, and others are expected to have a significant impact on the Lung Fibrosis market in the coming years.

• In April 2025, Endeavor BioMedicines (“Endeavor”), a clinical-stage biotech company focused on developing treatments for life-threatening diseases, has shared a post hoc analysis from its completed Phase 2a trial of ENV-101 (taladegib), its lead investigational therapy. The findings showed a notable decrease in pulmonary vessel volume, a significant increase in lung volume, and a trend toward reduced lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF) who received ENV-101 for 12 weeks compared to placebo. The analysis leveraged Qureight’s AI-powered CT imaging technology and was presented as a poster at the American Thoracic Society (ATS) 2025 International Conference.

• In April 2025, Avalyn Pharma Inc., a clinical-stage biopharma company focused on inhaled treatments for severe pulmonary conditions, announced that its investigational therapy AP02 (inhaled nintedanib) demonstrated a favorable safety and tolerability profile in multiple Phase 1 clinical trials. These included both single-ascending dose (SAD) and multiple-ascending dose (MAD) studies conducted in healthy adults and patients with idiopathic pulmonary fibrosis (IPF).

• In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a pioneering human IgG1 antibody aimed at inhibiting WISP1-driven fibrotic signaling in various severe diseases.

• In October 2024, Trevi Therapeutics, a company focused on developing the investigational therapy Haduvio (oral nalbuphine ER) for treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has shared updates on its clinical development program.

• In September 2024, Aileron Therapeutics announced that enrollment for Cohort 2 in the ongoing Phase Ib clinical trial of LTI-03 for IPF patients has been successfully completed.

• In July 2024, Bridge Biotherapeutics announced the completion of patient enrollment in the Phase II clinical trial of BBT-877, a novel autotaxin (ATX) inhibitor developed for the treatment of idiopathic pulmonary fibrosis (IPF).

• In July 2024, Huitai BioMedicine (HUITAI) announced that its first independently developed and globally patented innovative drug, inhaled HTPEP-001 for pulmonary fibrosis treatment, has successfully administered the first dose to a healthy subject in a Phase I clinical trial at Beijing Chaoyang Hospital.

Lung Fibrosis Overview

Lung fibrosis, also known as pulmonary fibrosis, is a chronic lung disease characterized by scarring (fibrosis) of lung tissue, leading to stiffness and reduced oxygen exchange. This progressive condition makes breathing difficult and can result from idiopathic pulmonary fibrosis (IPF), autoimmune diseases, infections, environmental exposures, or certain medications. Symptoms include persistent dry cough, shortness of breath, fatigue, and chest discomfort. There is no cure, but treatments such as antifibrotic drugs (pirfenidone, nintedanib), oxygen therapy, and pulmonary rehabilitation can help slow disease progression and improve quality of life. In severe cases, lung transplantation may be considered.

Get a Free Sample PDF Report to know more about Lung Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/lung-fibrosis-pipeline-insight

Emerging Lung Fibrosis Drugs Under Different Phases of Clinical Development Include:

• Pirfenidone: Genentech, Inc.

• BMS-986278: Bristol-Myers Squibb

• BI 1839100: Boehringer Ingelheim

• Pirfenidone: Assistance Publique – Hôpitaux de Paris

• Etanercept: Pfizer

• n-acetylcysteine: Zambon SpA

• CNTO 888: Centocor, Inc.

• TTI-101: Tvardi Therapeutics

• BMS-986278: Bristol-Myers Squibb

• Pirfenidone: PureTech

• taladegib: Endeavor Biomedicines

• Axatilimab: Syndax Pharmaceuticals

• SB17170: SPARK Biopharma

• Garadacimab: CSL Behring

Lung Fibrosis Route of Administration

Lung Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Lung Fibrosis Molecule Type

Lung Fibrosis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Lung Fibrosis Pipeline Therapeutics Assessment

• Lung Fibrosis Assessment by Product Type

• Lung Fibrosis By Stage and Product Type

• Lung Fibrosis Assessment by Route of Administration

• Lung Fibrosis By Stage and Route of Administration

• Lung Fibrosis Assessment by Molecule Type

• Lung Fibrosis by Stage and Molecule Type

DelveInsight’s Lung Fibrosis Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Lung Fibrosis product details are provided in the report. Download the Lung Fibrosis pipeline report to learn more about the emerging Lung Fibrosis therapies

Some of the key companies in the Lung Fibrosis Therapeutics Market include:

Key companies developing therapies for Lung Fibrosis are – Endeavor BioMedicines, Humanetics Corporation, Melius Pharma AB, Tvardi Therapeutics, GRI Bio Operations, Daewoong Pharmaceutical, Regend Therapeutics, Boehringer Ingelheim, Avalyn Pharmaceuticals, Syndax Pharmaceuticals, PureTech Health, Otsuka Holdings, Vicore Pharma, Sunshine Lake Pharma, and others.

Lung Fibrosis Pipeline Analysis:

The Lung Fibrosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Lung Fibrosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lung Fibrosis Treatment.

• Lung Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Lung Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lung Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Lung Fibrosis drugs and therapies

Lung Fibrosis Pipeline Market Drivers

• Rising Disease Prevalence, Advancements in Drug Development, Growing Research & Clinical Trials, Regulatory Support, Improved Diagnostic Techniques, are some of the important factors that are fueling the Lung Fibrosis Market.

Lung Fibrosis Pipeline Market Barriers

• However, High Drug Development Costs, Limited Treatment Options, Stringent Regulatory Approvals, Side Effects & Safety Concerns, Low Awareness & Late Diagnosis, and other factors are creating obstacles in the Lung Fibrosis Market growth.

Scope of Lung Fibrosis Pipeline Drug Insight

• Coverage: Global

• Key Lung Fibrosis Companies: Genentech, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Assistance Publique – Hôpitaux de Paris, Pfizer, Zambon SpA, Centocor, Inc., Tvardi Therapeutics, Bristol-Myers Squibb, PureTech, Endeavor Biomedicines, Syndax Pharmaceuticals, SPARK Biopharma, CSL Behring, and others

• Key Lung Fibrosis Therapies: Pirfenidone, BMS-986278, BI 1839100, Pirfenidone, Etanercept, n-acetylcysteine, CNTO 888, TTI-101, BMS-986278, Pirfenidone, taladegib, Axatilimab, SB17170, Garadacimab, and others

• Lung Fibrosis Therapeutic Assessment: Lung Fibrosis current marketed and Lung Fibrosis emerging therapies

• Lung Fibrosis Market Dynamics: Lung Fibrosis market drivers and Lung Fibrosis market barriers

Request for Sample PDF Report for Lung Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Lung Fibrosis Report Introduction

2. Lung Fibrosis Executive Summary

3. Lung Fibrosis Overview

4. Lung Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Lung Fibrosis Pipeline Therapeutics

6. Lung Fibrosis Late Stage Products (Phase II/III)

7. Lung Fibrosis Mid Stage Products (Phase II)

8. Lung Fibrosis Early Stage Products (Phase I)

9. Lung Fibrosis Preclinical Stage Products

10. Lung Fibrosis Therapeutics Assessment

11. Lung Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Lung Fibrosis Key Companies

14. Lung Fibrosis Key Products

15. Lung Fibrosis Unmet Needs

16 . Lung Fibrosis Market Drivers and Barriers

17. Lung Fibrosis Future Perspectives and Conclusion

18. Lung Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lung Fibrosis Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Zambon SpA, Centocor

DelveInsight’s “CTD-ILD Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the CTD-ILD, historical and forecasted epidemiology as well as the CTD-ILD market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of CTD-ILD, offering comprehensive insights into the CTD-ILD revenue trends, prevalence, and treatment landscape. The report delves into key CTD-ILD statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging CTD-ILD therapies. Additionally, we cover the landscape of CTD-ILD clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of CTD-ILD treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the CTD-ILD space.

To Know in detail about the CTD-ILD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; CTD-ILD Market Forecast

Some of the key facts of the Connective Tissue Disease associated with Interstitial Lung Disease Market Report:

• The CTD-ILD market size was valued ~USD 1,498 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In 2023, the United States held the largest market share for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), contributing approximately 70% of the total market size across the 7MM. This was significantly higher compared to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

• In 2023, Germany recorded the largest market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) among EU countries, reaching nearly USD 84 million, while Spain had the smallest market size at USD 38 million.

• Japan’s market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) was approximately USD 136 million in 2023, representing 9% of the total market across the 7MM.

• Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others

• Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others

• The CTD-ILD market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CTD-ILD pipeline products will significantly revolutionize the CTD-ILD market dynamics.

• According to DelveInsight’s evaluation, the total prevalent cases of Interstitial Lung Disease (ILD) in the 7MM were approximately 1,662,000 in 2023.

• In 2023, the United States recorded the highest number of diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), approximately 132,000, with numbers anticipated to increase in the future.

• Within Europe, the UK reported the highest number of diagnosed prevalent cases of CTD-ILD in 2023, approximately 27,000, followed by Germany with 25,000 cases. In contrast, Spain had the lowest prevalence, with around 11,000 cases.

• In 2023, Japan reported approximately 68,000 diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), representing around 23% of the total cases across the 7MM.

• In the US in 2023, type-specific diagnosed cases of CTD-ILD were highest for pSS-ILD (approximately 38,000), followed by SSc-ILD (around 31,000), Other CTD-ILDs (roughly 30,000), RA-ILD (about 20,000), DM-ILD/PM-ILD (close to 8,000), and SLE-ILD (nearly 5,000).

Connective Tissue Disease associated with Interstitial Lung Disease Overview

Connective Tissue Disease (CTD)-associated Interstitial Lung Disease (ILD) refers to a group of lung disorders that occur as a result of underlying connective tissue diseases. These diseases, such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and polymyositis, can cause inflammation and scarring in the lungs, leading to ILD. This condition results in impaired lung function, breathing difficulties, and decreased oxygen levels. The damage is often progressive and can lead to respiratory failure if left untreated. Early diagnosis and management are crucial to managing symptoms and slowing disease progression. Treatment typically involves immunosuppressive medications and management of the underlying CTD.

Get a Free sample for the CTD-ILD Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market

CTD-ILD Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Connective Tissue Disease associated with Interstitial Lung Disease Epidemiology Segmentation:

The CTD-ILD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of CTD-ILD

• Prevalent Cases of CTD-ILD by severity

• Gender-specific Prevalence of CTD-ILD

• Diagnosed Cases of Episodic and Chronic CTD-ILD

Download the report to understand which factors are driving CTD-ILD epidemiology trends @ CTD-ILD Epidemiology Forecast

CTD-ILD Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CTD-ILD market or expected to get launched during the study period. The analysis covers CTD-ILD market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the CTD-ILD Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

CTD-ILD Therapies and Key Companies

• Belimumab: GlaxoSmithKline

• bosentan: Actelion

• Tulisokibart: Prometheus Biosciences

• Rituximab: Eric Matteson

• Vixarelimab: Genentech, Inc.

• OFEV: Boehringer Ingelheim Pharmaceuticals, Inc.

• Belimumab, GSK1550188 (BENLYSTA): GlaxoSmithKline plc.

Discover more about therapies set to grab major CTD-ILD market share @ CTD-ILD Treatment Landscape

Connective Tissue Disease associated with Interstitial Lung Disease Market Drivers

• Increasing Prevalence of CTD-ILD

• Advances in Diagnostic Techniques

• Emergence of Novel Therapies

• Rising Awareness Among Healthcare Providers

• Aging Population

• Regulatory Approvals for Targeted Treatments

• Supportive Healthcare Policies

Connective Tissue Disease associated with Interstitial Lung Disease Market Barriers

• High Cost of Treatment

• Limited Drug Approvals

• Challenges in Early Diagnosis

• Heterogeneity of CTD-ILD

• Side Effects of Current Treatments

• Lack of Awareness in Emerging Markets

• Inconsistent Clinical Guidelines

Scope of the Connective Tissue Disease associated with Interstitial Lung Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others

• Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others

• CTD-ILD Therapeutic Assessment: CTD-ILD current marketed and CTD-ILD emerging therapies

• CTD-ILD Market Dynamics: CTD-ILD market drivers and CTD-ILD market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• CTD-ILD Unmet Needs, KOL’s views, Analyst’s views, CTD-ILD Market Access and Reimbursement

To know more about CTD-ILD companies working in the treatment market, visit @ CTD-ILD Clinical Trials and Therapeutic Assessment

Table of Contents

1. CTD-ILD Market Report Introduction

2. Executive Summary for CTD-ILD

3. SWOT analysis of CTD-ILD

4. CTD-ILD Patient Share (%) Overview at a Glance

5. CTD-ILD Market Overview at a Glance

6. CTD-ILD Disease Background and Overview

7. CTD-ILD Epidemiology and Patient Population

8. Country-Specific Patient Population of CTD-ILD

9. CTD-ILD Current Treatment and Medical Practices

10. CTD-ILD Unmet Needs

11. CTD-ILD Emerging Therapies

12. CTD-ILD Market Outlook

13. Country-Wise CTD-ILD Market Analysis (2020–2034)

14. CTD-ILD Market Access and Reimbursement of Therapies

15. CTD-ILD Market Drivers

16. CTD-ILD Market Barriers

17. CTD-ILD Appendix

18. CTD-ILD Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CTD-ILD Market Growth Projections 2024-2034: DelveInsight Analysis | GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim